Table 1.
Baseline characteristics of the study population
| Parameter | Tight control (n=101) | Standard care (n=105) | Total (n=206) |
|---|---|---|---|
| Male sex, n (%) | 53 (52·5) | 55 (52·4) | 108 (52·4%) |
| Age (years), median (IQR) | 46 (38, 55) | 45 (36, 51) | 45 (38, 53) |
| Ethnicity: Caucasian, n (%) | 92 (91·1) | 96 (91·4) | 188 (91·3) |
| Disease duration at randomisation (months) | 0·9 (0·5, 2·1) | 0·7 (0·4, 1·8) | 0·8 (0·4, 2·0) |
| Number of swollen joints (0-66), median (IQR) | 6.0 (3·0, 10·0) | 4.0 (2·0, 8·0) | 5·0 (2·0, 9·0) |
| Number of tender joints (0-68), median (IQR) | 9.0 (3·0, 19·0) | 9.0 (4·0, 17·0) | 9·0 (4·0, 18·0) |
| CRP(mg/dl), median (IQR) | 7.5 (5·0, 24·0) | 6.3 (5·0, 15·5) | 6·7 (5·0, 18·2) |
| Rheumatoid factor negative, n (%) | 94 (93·1) | 101 (96·2) | 195 (94·7) |
| CCP negative, n (%) | 87 (86·1) | 85 (81·0) | 172 (83·5) |
| Early morning stiffness (EMS), n (%) | 88 (87·1) | 96 (91·4) | 184 (89·3%) |
| EMS duration (hours), median (IQR) (patients with EMS) | 1·0 (0·5, 2·0) | 1·0 (0·5, 2·0) | 1·0 (0·5, 2·0) |
| Arthritis pattern, n (%) of patients | |||
| Polyarthritis (≥5 joints) | 72 (71·3) | 74 (70·5) | 146 (70·9) |
| Oligoarthritis (<5 joints) | 29 (28·7) | 31 (29.5) | 60 (29·1) |
| DIP disease | 18 (17·8) | 27 (25·7) | 45 (21·8) |
| Axial involvement | 20 (19·8) | 23 (21·9) | 43 (20·9) |
| Arthritis mutilans | 0 (0·0) | 0 (0·0) | 0 (0·0) |
| CASPAR criteria met (score ≥3), n (%) | 90 (89·1) | 98 (93·3) | 188 (91·3) |
| CASPAR score ≥2, n (%) | 99 (98·1) | 103 (98·1) | 202 (98·1) |
| Current psoriasis, n (%) | 81 (80·2) | 93 (88·6) | 174 (84·5) |
| PASI score (all patients), median (IQR) | 1·7 (0·4, 4·2) | 2·1 (0·8, 4·2) | 1·9 (0·6, 4·2) |
| PASI score (condition at baseline), median (IQR) | 2·6 (1·2, 4·8) | 2·5 (1·2, 4·7) | 2·6 (1·2, 4·8) |
| Current enthesitis, n (%) | 82 (81·2) | 80 (76·2) | 162 (78·6) |
| Enthesitis score (all patients), median (IQR) | 3·0 (1·0, 6·0) | 2·0 (1·0, 6·0) | 2·0 (1·0, 6·0) |
| Enthesitis score (condition at baseline), median (IQR) | 4.0 (2·0, 7·0) | 4.0 (2·0, 7·0) | 4.0 (2·0, 7·0) |
| Current dactylitis, n (%) | 35 (34·7) | 27 (25·7) | 62 (30·1) |
| Dactylitis score (all patients), median (IQR) | 0·0 (0·0, 22·0) | 0·0 (0·0, 0·0) | 0·0 (0·0, 13·0) |
| Dactylitis score (condition at baseline), median (IQR) | 36·0 (20·0, 67·0) | 41·0 (16·0, 112·0) | 37·0 (19·0, 96·0) |
| Current nail disease, n (%) | 62 (61·4) | 62 (59·0) | 124 (60·2) |
| mNAPSI score (all patients), median (IQR) | 2·0 (0·0, 10·0) | 1·5 (0·0, 11·5) | 2·0 (0·0, 10·0) |
| mNAPSI score (condition at baseline), median (IQR) | 8·5 (3·0, 15·0) | 8·0 (2·0, 23·0) | 8·0 (2·0, 19·0) |
CRP, C-reactive protein; CCP, cyclic citrullinated peptide antibody; CASPAR, ClASsification of Psoriatic Arthritis; PASI, Psoriasis Area Severity Index; mNAPSI, Modified Nail Psoriasis Severity Index.